Home > Rheumatology > ACR 2019 > Osteoarthritis – State-of-the-Art > Opioids: no quality of life benefits for OA patients

Opioids: no quality of life benefits for OA patients

Presented By
Dr Raveendhara Bannuru, Tufts Medical Center, USA
Conference
ACR 2019
A meta-analysis showed that particularly strong opioids should be avoided in osteoarthritis (OA) patients due to their unfavourable benefit-risk ratio [1]. The United States is in the throes of an opioid epidemic, a development that might spill over to Europe. However, opioids have major safety concerns. The lack of information about opioids’ efficacy for OA pain relief, and no clear delineation between overall efficacy and safety between strong and weak opioids, prompted the meta-analysis. “Given the current controversy regarding the use of opioids in chronic pain, we wanted to delve deeper into the efficacy and safety profiles of oral opioid drugs in OA patients. Temporal assessments can reveal peak periods of efficacy and can provide clinicians with a blueprint for optimal durations of treatment regimens,” said Dr Raveendhara Bannuru (Tufts Medical Center, Boston, USA), the study’s lead author. The meta-analysis assessed the role of weak versus s...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on